ClearPoint Neuro (CLPT) Common Equity (2011 - 2026)

ClearPoint Neuro has disclosed Common Equity across 16 years of filings, most recently posting $18.8 million for Q1 2026.

• Common Equity for Q1 2026 came in at $18.8 million, down 5.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.8 million (down 5.73% YoY), and the FY2025 annual result was $28.0 million, up 10.36% from the prior year.
• Common Equity came in at $18.8 million for Q1 2026 at ClearPoint Neuro, down from $28.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $45.7 million in Q1 2022 to a low of $15.9 million in Q3 2025.
• The 5-year median for Common Equity is $28.0 million (2025), against an average of $29.1 million.
• Across the five-year window, Common Equity climbed 20.37% in 2024 and plunged 45.26% in 2025, its largest moves.
• ClearPoint Neuro's Common Equity stood at $36.9 million in 2022, then slumped by 42.6% to $21.2 million in 2023, then climbed by 19.91% to $25.4 million in 2024, then grew by 10.36% to $28.0 million in 2025, then slumped by 32.76% to $18.8 million in 2026.
• The last three Common Equity figures came in at $18.8 million (Q1 2026), $28.0 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.